Smith & Nephew plc (LON:SN) Insider Buys £41,948.10 in Stock

Smith & Nephew plc (LON:SN) insider Sybella Stanley bought 3,810 shares of the business’s stock in a transaction on Wednesday, March 26th. The stock was purchased at an average cost of GBX 1,101 ($14.25) per share, with a total value of £41,948.10 ($54,294.72).

Smith & Nephew Price Performance

SN opened at GBX 1,071 ($13.86) on Friday. The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 70.22. The stock’s 50-day moving average is GBX 1,070.03 and its 200 day moving average is GBX 1,051.48. The company has a market cap of £11.74 billion, a price-to-earnings ratio of 38.56, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62.

Smith & Nephew Increases Dividend

The company also recently announced a dividend, which will be paid on Wednesday, May 28th. Investors of record on Thursday, March 27th will be paid a $0.23 dividend. This represents a dividend yield of 1.61%. This is an increase from Smith & Nephew’s previous dividend of $0.14. The ex-dividend date is Thursday, March 27th. Smith & Nephew’s payout ratio is presently 104.41%.

Analyst Upgrades and Downgrades

Separately, JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a GBX 1,180 ($15.27) price objective on shares of Smith & Nephew in a research note on Tuesday, January 14th.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.